Evidence map›Paper›PMID 41342736›Full record

ArticleBlood cancer discovery2026

Human TET2-Mutant Clonal Hematopoiesis Expansion Is Driven by Distinct Inflammatory Signaling Responses in Stem Cells Versus Myeloid Progeny.

Hector Huerga Encabo, Giuseppe D'Agostino, Katherine Sturgess, Alice E Lord, Eric D Jong, Alessandra Ferrelli, Aneesh Sharma, Syed A Mian, Khadidja Habel, Miriam Llorian-Sopena and 11 more

Abstract read
In one paragraph

Article in Blood cancer discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. The immunology behind inflammaging-causes, sources, and mechanisms.The Journal of allergy and clinical immunology · 2026
    Review
  3. Review
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Hector Huerga EncaboHaematopoietic Stem Cell Laboratory, The Francis Crick Institute, London, United Kingdom.ORCID 0000-0002-3723-8624
Giuseppe D'AgostinoPlasticell Limited , Stevenage, United Kingdom.ORCID 0000-0001-8315-7406
Katherine SturgessHaematopoietic Stem Cell Laboratory, The Francis Crick Institute, London, United Kingdom.ORCID 0000-0002-6969-4747
Alice E LordCentre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.ORCID 0000-0003-4238-4754
Eric D JongHaematopoietic Stem Cell Laboratory, The Francis Crick Institute, London, United Kingdom.ORCID 0000-0003-1117-9555
Alessandra FerrelliHaematopoietic Stem Cell Laboratory, The Francis Crick Institute, London, United Kingdom.ORCID 0000-0003-2308-1352
Aneesh SharmaHaematopoietic Stem Cell Laboratory, The Francis Crick Institute, London, United Kingdom.ORCID 0000-0002-8025-6772
Syed A MianHaematopoietic Stem Cell Laboratory, The Francis Crick Institute, London, United Kingdom.ORCID 0000-0001-8005-2860
Khadidja HabelHaematopoietic Stem Cell Laboratory, The Francis Crick Institute, London, United Kingdom.ORCID 0009-0007-6471-1468
Miriam Llorian-SopenaBioinformatics and Biostatistics, The Francis Crick Institute, London, United Kingdom.ORCID 0000-0003-2582-6602
Amirtha Priya RameshHaematopoietic Stem Cell Laboratory, The Francis Crick Institute, London, United Kingdom.ORCID 0000-0003-4936-7754
Fatihah Mohamad NorHaematopoietic Stem Cell Laboratory, The Francis Crick Institute, London, United Kingdom.ORCID 0009-0003-6787-0713
Helene FoissnerHaematopoietic Stem Cell Laboratory, The Francis Crick Institute, London, United Kingdom.ORCID 0009-0000-0378-4961
Manuel Garcia-AlbornozHaematopoietic Stem Cell Laboratory, The Francis Crick Institute, London, United Kingdom.ORCID 0000-0002-2300-2047
Lynette GraverHaematopoietic Stem Cell Laboratory, The Francis Crick Institute, London, United Kingdom.ORCID 0000-0002-1267-5916
Despoina PapazoglouHaematopoietic Stem Cell Laboratory, The Francis Crick Institute, London, United Kingdom.ORCID 0009-0008-5818-8663
Steven NgoHaematopoietic Stem Cell Laboratory, The Francis Crick Institute, London, United Kingdom.ORCID 0000-0003-0132-873X
Fernando Anjos-AfonsoHaematopoietic Stem Cell Laboratory, The Francis Crick Institute, London, United Kingdom.ORCID 0000-0003-4392-488X
Linda Ariza-McNaughtonHaematopoietic Stem Cell Laboratory, The Francis Crick Institute, London, United Kingdom.ORCID 0000-0002-8900-0984
Gabriella FiczCentre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.ORCID 0000-0001-9313-9578
Dominique BonnetHaematopoietic Stem Cell Laboratory, The Francis Crick Institute, London, United Kingdom.ORCID 0000-0002-4735-5226

Funding

European Hematology Association (EHA) Kick-off grantKay Kendall Leukaemia Fund (KKLF) KKL1397Medical Research Council CC2027Wellcome Trust CC2027
6 · The paper itself

Abstract

Clonal hematopoiesis (CH) increases with age and is associated with severe outcome in the course of infections or tumor development. Understanding the environmental conditions that favor mutant clones and the CH immune system response to such environments is key to designing therapeutic strategies to stall the expansion of mutant clones and the development of CH-associated pathologies. Using human cells, we unravel a cell-specific and opposite impact of TET2 mutations on hematopoietic stem and progenitor cells (HSPC) compared with their myeloid progeny. Multi-omic analyses reveal that TET2-mutant HSPCs exhibit intrinsic epigenetic silencing of AP-1 transcription factors and a blunted transcriptional adaptation to systemic inflammation. Conversely, monocyte-macrophage trajectory derived from TET2Mut hematopoietic stem cells (HSC) contributes to exacerbated inflammation. Together, these findings reconcile how TET2-mutant CH can simultaneously promote increased stemness within the HSPC compartment and heightened inflammation through its myeloid progeny, providing mechanistic insight into how TET2-CH expands under inflammatory stress. SIGNIFICANCE: This study reveals that stress conditions inducing emergency myelopoiesis expand human TET2-mutant clones. TET2 mutation triggers an epigenetic silencing of AP-1 factors contributing to the dampening of the inflammatory responsiveness in TET2mut HSPCs while simultaneously promoting hyperinflammatory TET2mut monocyte-macrophage activation and differentiation, reinforcing inflammation.

Indexed as

Clonal HematopoiesisDNA-Binding ProteinsHematopoietic Stem CellsInflammationMutationMyeloid CellsProto-Oncogene ProteinsDioxygenasesEpigenesis, GeneticHumansSignal TransductionDioxygenasesDNA-Binding ProteinsProto-Oncogene ProteinsTET2 protein, human

Identifiers

PMID41342736
PMCPMC7618546

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.